A 72-year-old woman with poorly controlled hypertension is brought to hospital with acute right-sided weakness and altered consciousness. Non-contrast CT head shows a 4 cm hyperdense lesion in the left basal ganglia with mass effect and midline shift. The patient is on warfarin for atrial fibrillation (INR 3.2). What is the most appropriate immediate next step?

Explanation

## Clinical Scenario Analysis The patient presents with acute intracerebral hemorrhage (ICH) with significant mass effect (midline shift) and altered consciousness—a neurosurgical emergency. She is on warfarin with supratherapeutic INR (3.2), which likely contributed to the hemorrhage and requires urgent reversal. ## Immediate Management Priorities in Warfarin-Associated ICH **High-Yield:** In a patient with warfarin-associated ICH and mass effect, the dual priorities are: 1. **Urgent reversal of anticoagulation** to prevent hematoma expansion 2. **Neurosurgery consultation** for potential surgical evacuation (mass effect + altered consciousness = surgical candidate) **Key Point:** FFP provides immediate clotting factors (II, VII, IX, X) to reverse warfarin effect within minutes, while vitamin K takes 12–24 hours to take effect. In acute ICH with mass effect, immediate reversal is critical. ## Warfarin Reversal Agents: Comparison | Agent | Onset | Duration | Indication | Limitation | |-------|-------|----------|-----------|------------| | **Fresh Frozen Plasma (FFP)** | Minutes | 4–6 hours | Immediate reversal when prothrombin complex concentrate (PCC) unavailable | Large volume required; risk of fluid overload | | **Prothrombin Complex Concentrate (PCC)** | Minutes | 12–24 hours | Preferred agent for warfarin reversal in ICH | May not be available in all Indian hospitals | | **Idarucizumab** | Minutes | 24 hours | Reversal of dabigatran (direct thrombin inhibitor), NOT warfarin | Incorrect agent for warfarin reversal; expensive | | **Vitamin K** | 12–24 hours | Days | Sustained reversal; used adjunctively | Too slow for acute ICH | **Clinical Pearl:** Idarucizumab reverses dabigatran, not warfarin. Using it here would be both ineffective and wasteful. ## Management Algorithm for Warfarin-Associated ICH ```mermaid flowchart TD A["Warfarin-associated ICH on CT"]:::outcome --> B{"Mass effect or altered consciousness?"}:::decision B -->|"Yes"|C["STAT FFP or PCC + Vitamin K"]:::action B -->|"No"|D["Vitamin K + supportive care"]:::action C --> E["Neurosurgery consultation"]:::action E --> F{"Surgical candidate?"}:::decision F -->|"Yes (volume >30 mL, midline shift, GCS <8)"|G["Hematoma evacuation"]:::action F -->|"No"|H["ICU monitoring + repeat CT"]:::action D --> I["Monitor for expansion"]:::action ``` **Key Point:** The presence of mass effect (midline shift) and altered consciousness (GCS <8 implied) makes this patient a surgical candidate. Neurosurgery must be consulted urgently alongside anticoagulation reversal. ## Why CTA is NOT the Immediate Next Step **Warning:** While CTA may eventually be useful to exclude underlying vascular lesions (AVM, aneurysm), it should NOT delay anticoagulation reversal and neurosurgery consultation in a patient with acute mass effect. Time is brain—imaging can be obtained after urgent clinical decisions are made. ## Supportive Measures - **Mannitol/hypertonic saline:** Used for ICP management but are temporizing measures, not definitive treatment in surgical candidates - **Hyperventilation:** Temporary measure (lowers PaCO~2~, reduces cerebral blood volume); not a substitute for evacuation - **Repeat CT in 6 hours:** Delays definitive intervention; inappropriate when mass effect is already present